Supply of Veklury (Remdesivir) for the Treatment of Covid-19 Patients Requiring Supplemental Oxygen

The subject of this call for tenders is the supply of Remdesivir. Remdesivir has been authorised for marketing in the European Union under the invented name Veklury, since 3 July 2020. It has a conditional marketing authorisation for the treatment of Covid-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen.

The subject of this contract is the supply of vials of Veklury (remdesivir) 100 mg powder for concentrate for solution for infusion that has a conditional marketing authorisation (EU/1/20/1459/002) for the treatment of Covid-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen.